Paediatric respiratory disease has changed in the past 20 yrs; we could fill a whole issue of the journal paying tribute to our famous forebears. We are posing new challenges to our colleagues in the field of adult respiratory disease. They have to learn to deal with conditions that 20 yrs ago were rare in the adult chest clinic, such as cystic fibrosis (CF) and the long-term consequences of premature birth and congenital malformations of the respiratory tract. Furthermore, studies in childhood are challenging pathophysiological concepts throughout life.

The many great prospective birth cohort studies have shed light on the different patterns of wheezing, their risk factors and their evolution through childhood. Who would have thought it was good to be born in a barn! It is becoming increasingly clear that even for “adult” diseases, such as chronic obstructive pulmonary disease (COPD), antenatal and early life events are at least as important as smoking in adulthood [1]. CF has become a disease also of adults [2]. Although many factors have contributed, the main reason has been the development of expert special CF centres, a model increasingly adopted by adult teams. This can serve as a model for other diseases; how a well-structured multidisciplinary approach to treatment can translate into benefits for patients. Perhaps numerically the most important achievement is in the field of public health. The benefit of the decrease in invasive bacterial infections, due to vaccination programmes for infants, is among the most important achievements of the past.

Other areas of change include the survival of ever smaller preterm neonates. These children are reaching adult life with impaired lung function and abnormal computed tomography scans. What will happen to their ageing lungs? Interstitial lung disease (ILD) is becoming increasingly well understood, with new genetic entities, such as surfactant protein C mutations, having relevance to adult ILD [3]. The advent of powerful new therapies, in particular antibiotics and anti-inflammatories, has led to the need for better monitoring tools, including bronchoscopes small enough to examine even preterm babies, and novel physiological testing. Specific future challenges are dealt with below; first, specific disease areas; secondly, monitoring tools; and, thirdly, paediatric intensive care.

**SPECIFIC DISEASES**

**The newborn child**

Much progress has been made in neonatal practice including better application of established therapies such as antenatal corticosteroids and exogenous surfactants, and recognition of their long-term effects. This lesson has also resulted in larger trials, such as the use of nitric oxide in preterm infants [4] and noninvasive ventilation, in this population [5]. Physiological definitions have been improved (such as that of chronic lung disease of prematurity (CLD) or bronchopulmonary dysplasia (BPD)) and ongoing trials throughout the world are focusing on the optimal oxygen saturations for preterm infants (BOOST (Benefits of Oxygen Saturation Targeting) and BOOST 2). Longer term respiratory outcomes are essential to determine if prematurity is a risk factor for development of COPD, and there is increasing recognition that children with mild neonatal lung disease may have significant long-term consequences [6]. The recognition of antenatal infection with *Ureaplasma* spp. [7] as a cause of preterm birth is re-emerging as potential treatable option to decrease the burden of CLD/BPD.

**Paediatric asthma**

Childhood asthma will continue to be a main focus of the speciality. Although prevalence may have plateaued in parts of the developed world, it is rising elsewhere [8]. New approaches to the understanding of underlying mechanisms increasingly depend upon phenotype characterisation [9], and cutting-edge biology techniques are needed to define phenotypes, as exemplified by U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes), a partnership between academia and industry under the Innovative Medicines Initiative of the European Union. The very early origins of asthma, including antenatal lung health, will continue to be a focus [10, 11], particularly including epigenetic mechanisms.

Allergic sensitisation is a common, but not obligate, feature of asthma. Immunoglobulin E sensitisation to specific allergens alone is not sufficient to produce allergic disease. Recent discoveries have focused upon epithelial barrier function;
ORMDL3, recently shown to be important in sphingomyelin metabolism [12], and the genes expressed in the epithelium, e.g. filaggrin [13], are implicated in asthma. Does the combination of reduced barrier function in concert with infection and allergen exposure lead to asthma?

Although many children with asthma are easily treated with low-dose inhaled corticosteroids, a hard core of severe therapy-resistant asthmatics continue to be symptomatic. The challenge will be to characterise these children, and select the appropriate novel, likely cytokine-specific therapy, for the individual. We must find a way of safely and ethically testing these medications in children.

**Cystic fibrosis**

The past focus on symptomatic therapies has been important, but a better understanding of the cellular consequences of cystic fibrosis transmembrane conductance regulator (CFTR) mutations has led to strategies that target the primary abnormality. Gene therapy, CFTR-specific pharmacotherapy and ion channel modulators are currently in clinical trials and some compounds will probably become available in the near future [14]. Ultimately, combination therapy addressing different aspects of cellular dysfunction (e.g. intracellular trafficking and channel opening) may show the highest efficacy, but defining the best combinations will be challenging.

Newborn screening will probably become available throughout Europe in the next decade. An early diagnosis and implementation of CF care alone will not be sufficient to avoid early lung damage [15]. While studies are currently underway to find more efficacious early intervention strategies, there are no validated outcome measures for infants and young children. Therefore, in parallel to developing new therapies, validation of new outcome measures is a high priority for the near future [16].

**Primary ciliary dyskinesia and non-CF bronchiectasis**

In primary ciliary dyskinesia (PCD), knowledge of the spectrum of gene mutations and their functional consequences will, most likely, increase. In combination with noninvasive screening tests, such as measurement of nasal nitric oxide, this knowledge will help to clarify the incidence of this under-diagnosed disease [17]. Ciliopathy is an expanding spectrum: ciliary dysfunction has been found in cystic kidney and liver disease, retinitis pigmentosa, heterotaxy and congenital heart disease, and complex syndromes. The multiple functions of primary, nodal and motile cilia are only just becoming understood, and these will undoubtedly be a major research thrust. Treatment strategies have been largely copied from CF. Longitudinal observational studies will help to define key factors that drive structural airway damage in both PCD and non-CF bronchiectasis.

**Paediatric sleep medicine**

Current research focuses on assessing the prevalence of obstructive sleep apnoea (OSA) and on the relationship of OSA with subsequent cardiovascular disease, neurological impairment and metabolic syndrome. The treatment of OSA in children is not easy or straightforward, and at present there are very few data on what the threshold for treatment should be, or what the consequences of under-treatment would be [18]. Paediatric sleep medicine is one of many areas that will be impacted by the epidemic of childhood obesity. The research focus in this field will be upon development of clinical pathways for screening children at risk and identification of trigger points that lead to more detailed investigation or intervention.

**Paediatric lung transplantation**

Paediatric lung transplantation is a much smaller field than adult lung transplantation. It is, therefore, inevitable that paediatric specific research is limited, and that many advances follow on from adult research and practice. The improved outcomes reported in adults have also been reported in paediatric subjects, with international data now reporting a median post-transplantation survival of ~5 yrs, and some centres reporting outcomes better than this [19]. The focus of the next decade will be collaboration with adult colleagues to establish a new definition of bronchiolitis obliterans syndrome and chronic graft dysfunction, which in turn can act as a springboard for a better understanding of the pathophysiology and potential treatment of this heterogeneous condition.

**MONITORING TOOLS**

**Paediatric respiratory physiology**

The past decade has seen important advances in respiratory physiology in children of all ages. There has been further standardisation of infant lung function testing, to the point where a great majority of infant lung function laboratories now use commercial equipment and perform testing according to internationally agreed protocols. In the same period, the gap between infant lung function and school age lung function has been bridged. Collaboration between international groups of researchers on standardisation and quality control has culminated in publication of a joint European Respiratory Society/ American Thoracic Society guideline in 2007 [20]. The third major feature of the last decade has been a resurgence of interest in alternative functional measurements. Inert gas washout, oscillometry, interrupter resistance, plethysmographic airway resistance and structured light plethysmography have all made great advances. In many cases these are not new techniques but developments and modifications of old ideas.

The challenge of the next decade will be to provide clinicians and researchers with new tools for the management of individual patients and as outcome measures in epidemiological and intervention studies.

**Paediatric airway endoscopy**

Ultrasafe flexible instruments with a working channel of 1.2 mm can be used to traverse and examine the entire airway, from nostril to bronchus with minimal mechanical distortion of the airway anatomy and dynamics.

Today, paediatric flexible bronchoscopy (FB) is a well-established diagnostic investigation. The evaluation of airways obstruction, which may involve the upper and lower airway or both, is the most common indication for FB in infants [21]. The diagnostic yield of FB in many clinical circumstances can be increased by the information obtained with bronchoalveolar lavage (BAL) [22]. BAL is an important tool in the diagnosis of
l lung infection in both immunocompromised and immuno-
compotent children, because pathogens can easily be identified 
from small BAL samples. In children with chronic ILDs, BAL 
may have an important role in excluding or confirming a 
specific diagnosis, in characterising the alveolitis and in 
monitoring the patient during treatment and follow-up.

Interventional bronchoscopy is increasingly important, and 
involve the restoration of airway patency or instability, or the 
removal of tissue or substances from the airways or alveolar 
spaces that interfere with normal function. Interventional 
bronchoscopy includes laser therapy, dilatation of airway 
stenosis, placement of a stent, total lung lavage and treatment 
of bronchopleural fistulae [23]. Our colleagues in adult practice 
are ahead of us with techniques such as endobronchial 
ultrasound; as the equipment is miniaturised, children will 
be able to benefit from the techniques. Better instruments, 
better training and better research applications of endoscopy to 
 improve our understanding of paediatric respiratory diseases 
are still needed.

INTENSIVE CARE
In paediatric intensive care there has been major progress. 
Protection of the lung against ventilator-induced barotrauma 
and volutrauma continues to press us to reduce pressures and 
volumes. Newer technology in ventilators is helping with this, 
and the prospect of patient-driven ventilators (e.g. neurally 
adjusted ventilatory assist) is close. Our understanding of 
ventilator-associated infection also helps to minimise morbidi-
ty, and lessons from adult practice are showing us how 
avoidable such complications are. There is also a growing 
recognition that the longer term care of children with 
neuromuscular disease needs addressing [24].

A GLORIOUS PAST, A GREAT FUTURE
The number of surviving children born very prematurely 
(before 25 weeks gestation, birth weight <500 g) will increase. 
For adult physicians, this will be a new population at high risk 
for COPD.

Virus-induced bronchitis and bronchiolitis will continue to be a 
cause of respiratory morbidity in infants and pre-school children.
There is no effective treatment for bronchiolitis, and this is a gap 
that must be plugged. Further development of vaccines for 
prevention of early infections could have a major impact on risk 
of asthma later in childhood. We need strategies to prevent 
episodic (viral) wheeze progressing to multiple trigger wheeze 
and asthma. We know that inhaled corticosteroids are not able to 
prevent this change. Novel insights are needed.

Asthma is and will be the most common chronic disease in 
school children and adolescents. In allergic rhinitis and 
asthma, new individualised allergy vaccines could become a 
possible treatment to prevent asthma and/or deterioration. 
Novel therapies and biomarkers to select children and monitor 
the effects of treatment will be essential.

In CF diagnosed by newborn screening, we need new 
therapeutic combinations to change morbidity. As genotype-
specific treatments become available and, most likely, are 
applied to young children before the disease has progressed, 
we need biomarkers to select those at risk of more rapid 
deterioration, and validated end-points in very young children,
in order to assess the response to treatment. The risk from the 
recrudescence of tuberculosis and, especially, multidrug-resis-
tant and extensively drug-resistant disease requires multi-
professional and international attention. The same is true for 
other emerging infections, for example methicillin-resistant 
Staphylococcus aureus. New diagnostic tools, such as interferon-γ 
assays, might provide more specific test results than the 
tuberculin skin test.

We will become better and better at salvaging the very sick 
child. Chemotherapy for cancer, and transplantation of bone 
marrow, lung and other solid organs will improve the 
prognosis of malignancy and progressive lung diseases like 
ILD in children. Conversely, this will lead to increased 
pulmonary complications. We need to be alert to detect and 
properly manage these new complications.

The use of technology, both noninvasive and invasive, to keep 
children with neurological and airway diseases alive and at 
home will become increasingly important. As ever smaller 
children use these techniques, development of child-specific 
machines and interfaces will become ever more important.

Orphan lung diseases, such as pulmonary fibrosis of unknown 
origin, autoimmune diseases with lung complications, ILD and 
genital malformations of the respiratory tract, will continue 
to pose a burden on healthcare and require highly specialised 
tertiary care centres. Increasingly, international networks are 
cooperating to accumulate big series of patients to learn more 
about these patients.

So what are the themes of the past decades, and for the future? 
Much work has been done, but many more questions are being 
developed [25]; above all, we need horizontal collaboration 
between groups of specialist paediatric pulmonologists, and 
vertical collaboration with adult respiratory colleagues. The 
future is with the young paediatric pulmonologists, and we 
must ensure that they have the best possible training; the 
pHERMES initiative bids fair to deliver this [26]. Floreat ERS!

STATEMENT OF INTEREST
A statement of interest for E. Baraldi can be found at www.erj.
ersjournals.com/misc/statements.dtl

REFERENCES
1 Svanes C, Sunyer J, Plana E, et al. Early life origins of chronic 
obstructive pulmonary disease. Thorax 2010; 65: 14–20.
2 Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality 
and survival in the UK: 1947–2003. Eur Respir J 2007; 29: 522–526.
3 Bush A, Nicholson A. Paediatric interstitial lung disease. Eur 
Respir Mon 2008; 46: 319–354.
4 Ballard RA, Truog WE, Cnaan A, et al. NO CLD Study Group. 
Inhaled nitric oxide in preterm infants undergoing mechanical 
ventilation. N Engl J Med 2006; 355: 343–353.
5 Morley CJ, Davis PC, Doyle LW, et al. Nasal CPAP or intubation at 
birth for very preterm infants. N Engl J Med 2008; 358: 700–708.
6 Vrijlandt EJ, Boezen HM, Gerritsen J, et al. Respiratory health in 
prematurely born preschool children with and without broncho-
 pulmonal dysplasia. J Pediatr 2007; 150: 256–261.
7 Poglasge GR, Dalton RG, Nitsos I, et al. Pulmonary vascular and 
alveolar development in preterm lambs chronically colonized with 
Ureaplasma parvum. Am J Physiol Lung Cell Mol Physiol 2010; [Epub 
ahead of print DOI: 10.1152/ajplung.00369.2009].
Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733–743.

Smith JA, Drake R, Simpson A, et al. Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med 2008; 177: 1358–1363.

Haland G, Carlsen KC, Sandvik L, et al. Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med 2006; 355: 1682–1689.

Turner SW, Young S, Goldblatt J, et al. Childhood asthma and increased airway responsiveness: a relationship that begins in infancy. Am J Respir Crit Care Med 2009; 179: 98–104.

Moffat MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448: 470–473.

Müller S, Marenholz I, Lee YA, et al. Association of Filaggrin loss-of-function-mutations with atopic dermatitis and asthma in the Early Treatment of the Atopic Child (ETAC) population. Pediatr Allergy Immunol 2009; 20: 358–361.

Kreindler JL. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther 2010; 125: 219–229.

Stick SM, Brennan S, Murray C, et al. Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155: 623–628.

Zemanick ET, Harris JK, Conway S, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2010; 9: 1–16.

Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009; 34: 1264–1276.

Kaditis AG, Alexopoulos EI, Dalapascha M, et al. Cardiac systolic function in Greek children with obstructive sleep-disordered breathing. Sleep Med 2010; 11: 406–412.

Aurora P, Edwards LB, Christie JD, et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report – 2009. J Heart Lung Transplant 2009; 28: 1023–1030.

Beydon N, Davis SD, Lombardi E, et al. American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An official American Thoracic Society/European Respiratory Society statement: Pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007; 175: 1304–1345.

Midulla F, de Blic J, Barbato A, et al. Flexible endoscopy of paediatric airways. Eur Respir J 2003; 22: 698–708.

de Blic J, Midulla F, Barbato A, et al. Bronchoalveolar lavage in children. Eur Respir J 2000; 15: 217–231.

Priftis KN, Antracopoulos MB, Eber E, et al. eds. Paediatric Bronchoscopy (Progress in Respiratory Research, volume 38). Basel, Karger, 2010.

Fauroux B, Aubertin G, Clément A, et al. Which tests may predict the need for noninvasive ventilation in children with neuromuscular disease? Respir Med 2009; 103: 574–581.

Smyth AR, Barbato A, Beydon N, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 2010; 35: 247–265.

Gappa M, Noel J-L, Severin T, et al. Paediatric HERMES: a European syllabus in paediatric respiratory medicine. Breathe 2009; 5: 237–247.